Wedbush Forecasts Higher Earnings for Neurocrine Biosciences

Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) - Research analysts at Wedbush boosted their Q2 2025 earnings estimates for Neurocrine Biosciences in a research report issued on Tuesday, May 6th. Wedbush analyst L. Chico now expects that the company will post earnings per share of $1.12 for the quarter, up from their previous estimate of $1.11. Wedbush currently has a "Outperform" rating on the stock. The consensus estimate for Neurocrine Biosciences' current full-year earnings is $4.28 per share. Wedbush also issued estimates for Neurocrine Biosciences' Q3 2025 earnings at $1.34 EPS, Q4 2025 earnings at $1.38 EPS, FY2025 earnings at $3.92 EPS, FY2026 earnings at $5.77 EPS, FY2027 earnings at $8.90 EPS, FY2028 earnings at $10.49 EPS and FY2029 earnings at $13.78 EPS.

Several other brokerages also recently commented on NBIX. JPMorgan Chase & Co. lifted their target price on shares of Neurocrine Biosciences from $183.00 to $184.00 and gave the stock an "overweight" rating in a report on Wednesday, March 26th. Needham & Company LLC lifted their price objective on Neurocrine Biosciences from $138.00 to $139.00 and gave the stock a "buy" rating in a research note on Tuesday, May 6th. Evercore ISI lowered their target price on Neurocrine Biosciences from $190.00 to $185.00 and set an "outperform" rating on the stock in a research report on Thursday, April 24th. BMO Capital Markets lifted their target price on shares of Neurocrine Biosciences from $96.00 to $115.00 and gave the stock a "market perform" rating in a research report on Tuesday, May 6th. Finally, HC Wainwright dropped their price objective on shares of Neurocrine Biosciences from $185.00 to $168.00 and set a "buy" rating on the stock in a report on Tuesday, April 22nd. Three research analysts have rated the stock with a hold rating and twenty have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $162.00.

Neurocrine Biosciences Stock Performance

Neurocrine Biosciences stock traded up $2.03 during midday trading on Friday, reaching $118.90. The stock had a trading volume of 1,060,247 shares, compared to its average volume of 1,119,774. The stock has a market capitalization of $11.77 billion, a P/E ratio of 36.14, a price-to-earnings-growth ratio of 0.77 and a beta of 0.26. The firm's fifty day simple moving average is $106.44 and its 200-day simple moving average is $121.89. Neurocrine Biosciences has a 1-year low of $84.23 and a 1-year high of $157.98.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last announced its earnings results on Monday, May 5th. The company reported $0.08 EPS for the quarter, missing the consensus estimate of $0.70 by ($0.62). The business had revenue of $572.60 million for the quarter, compared to the consensus estimate of $587.06 million. Neurocrine Biosciences had a return on equity of 13.38% and a net margin of 14.49%. Neurocrine Biosciences's revenue for the quarter was up 11.1% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.20 EPS.

Institutional Trading of Neurocrine Biosciences

Several institutional investors have recently made changes to their positions in NBIX. Golden State Wealth Management LLC purchased a new position in Neurocrine Biosciences in the 4th quarter worth approximately $25,000. Huntington National Bank boosted its holdings in Neurocrine Biosciences by 73.5% in the fourth quarter. Huntington National Bank now owns 229 shares of the company's stock worth $31,000 after purchasing an additional 97 shares during the period. Brooklyn Investment Group increased its position in Neurocrine Biosciences by 99.1% in the fourth quarter. Brooklyn Investment Group now owns 231 shares of the company's stock worth $32,000 after buying an additional 115 shares during the period. GeoWealth Management LLC raised its holdings in shares of Neurocrine Biosciences by 65.4% during the fourth quarter. GeoWealth Management LLC now owns 258 shares of the company's stock valued at $35,000 after buying an additional 102 shares during the last quarter. Finally, Smallwood Wealth Investment Management LLC bought a new position in shares of Neurocrine Biosciences in the first quarter worth $34,000. 92.59% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, insider Julie Cooke sold 1,551 shares of the firm's stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $116.78, for a total value of $181,125.78. Following the completion of the sale, the insider now owns 19,544 shares in the company, valued at approximately $2,282,348.32. This trade represents a 7.35% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director William H. Rastetter sold 30,000 shares of the company's stock in a transaction dated Monday, May 5th. The stock was sold at an average price of $110.20, for a total transaction of $3,306,000.00. Following the transaction, the director now owns 37,491 shares in the company, valued at $4,131,508.20. The trade was a 44.45% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 39,953 shares of company stock worth $4,467,990 over the last 90 days. 4.80% of the stock is owned by insiders.

Neurocrine Biosciences declared that its board has initiated a share repurchase program on Friday, February 21st that permits the company to buyback $500.00 million in outstanding shares. This buyback authorization permits the company to repurchase up to 4.2% of its shares through open market purchases. Shares buyback programs are usually an indication that the company's leadership believes its shares are undervalued.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.